Pharma menace Martin Shkreli's old company to pay up to $40M to states for Daraprim price gouging

Zachary Brennan

Senior Editor

The Federal Trade Commission and seven states on Tuesday announced a new order under which the states will recoup $40 million from pharma badboy Martin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pharma menace Martin Shkreli's old company to pay up to $40M to states for Daraprim price gouging

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Phar­ma men­ace Mar­tin Shkre­li's old com­pa­ny to pay up to $40M to states for Dara­prim price goug­ing

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pharma menace Martin Shkreli's old company to pay up to $40M to states for Daraprim price gouging